KYNVIT
Live / Applied — Third extension granted (statement of use) (as of 19 Dec 2025)
What this means for you
Not registered yet, but its 10 Jul 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98077166
- Mark type
- Stylized text
- Filed
- 10 Jul 2023
- Published for opposition
- 30 Apr 2024
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma; all of the above excluding pharmaceutical preparations for the treatment of adenosine deaminase deficiency called SCID-ADA and excluding pharmaceutical preparations for the prevention and treatment of cancer and tumors
Owner
- Novartis AG, Basel, CH
- Novartis AG, Basel, CH
Prior registrations
Prosecution history
- 19 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Dec 2025 — SOU EXTENSION 3 GRANTED
- 19 Dec 2025 — SOU EXTENSION 3 FILED
- 19 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 24 Jun 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Jun 2025 — SOU EXTENSION 2 GRANTED
- 23 Jun 2025 — SOU EXTENSION 2 FILED
- 23 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 20 Dec 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 Dec 2024 — SOU EXTENSION 1 GRANTED
- 20 Dec 2024 — SOU EXTENSION 1 FILED
- 20 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 25 Jun 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 30 Apr 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 30 Apr 2024 — PUBLISHED FOR OPPOSITION